PNC-27 is a chimeric peptide (~3,000 g/mol) composed of a p53 protein binding domain fused to a cell-penetrating/membrane-lytic domain. It is designed to selectively bind HDM-2 (human homolog of MDM-2) expressed on the surface of cancer cells, creating membrane pores that trigger necrosis specifically in malignant cells while sparing normal cells. It has shown selectivity for cancer cells in vitro but has NO human clinical trials. The FDA has explicitly warned that PNC-27 products are unapproved drugs being marketed illegally.
2 independent Janoshik purity tests cover PNC-27 across 2 vendors. Results range from 99.0% to 99.3%.
Category: Cancer Research. Evidence rating: D (animal/preclinical only).
Clinical status: No human clinical trials. In vitro cell culture studies only. FDA has issued explicit warnings against PNC-27 products.
PNC-27 contains a 12-residue p53 peptide sequence that binds to HDM-2 (MDM-2 in humans), a protein normally found in the nucleus but abnormally expressed on the outer cell membrane of many cancer cell types. When PNC-27 binds membrane-bound HDM-2, its lytic domain forms pores in the cancer cell…
Safety considerations: No human safety data exists; In vitro selectivity for cancer cells suggests theoretical safety, but in vivo pharmacokinetics are unknown; No animal toxicology studies published.
Reviewed by the PeptideAtlas Editorial Team.
| Molecular weight | ~3,000 g/mol |
|---|---|
| Half-life | Unknown (no pharmacokinetic studies) |
| Production method | synthetic |
| Anti-doping status | not-listed |
| US regulatory status | NOT FDA-approved. FDA has issued explicit warnings that PNC-27 products are unapproved new drugs marketed in violation of federal law. |
| Vendor | Best tested purity |
|---|---|
| Eros Peptides | 99.3% |
| Turtle Treasures | 99.0% |
No. PNC-27 has shown selective cancer cell killing in laboratory cell cultures only. It has never been tested in humans or even in animal tumor models with published results. There is no evidence it can treat cancer in living organisms. The FDA has explicitly warned against PNC-27 products.
The FDA has issued warnings that PNC-27 products being sold commercially are unapproved drugs. Sellers have faced enforcement actions. It may be obtained as a research chemical for laboratory use, but marketing it for human consumption is illegal.
PNC-27 is an experimental peptide researched for its potential selective effects on abnormal cells while sparing healthy cells.
PNC-27 has been studied for: Anti-cancer research, Selective cell targeting. Experimental; selective cell research.
Contains HDM-2 binding domain that may selectively target cells with altered p53 expression.